Envoy Medical interim CFO gets 15,000 stock options

Envoy Medical, Inc. reported that Interim CFO Robert Potashnick received a grant of stock options on February 5, 2026.

Rhea-AI Filing Summary

Envoy Medical, Inc. reported that Interim CFO Robert Potashnick received a grant of stock options on February 5, 2026. The award covers 15,000 options to purchase Class A common stock at an exercise price of $0.53 per share, held directly.

The vesting schedule is structured so that 3,750 options vest on February 5, 2027, with the remaining 11,250 options vesting pro rata on the 5th of each month over the following 36 months. This aligns the Interim CFO’s compensation with longer-term company performance.

Insider Trade Summary

Grant/Award: 15,000 shares

Grant/Award 1 txn

Insider Potashnick Robert

Role Interim CFO

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	15,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 15,000 contracts (Direct)

Footnotes (1)

1. F1. Options to purchase 3,750 shares vest on 2/5/2027, and 11,250 shares vest pro rata on the 5th of each month thereafter for 36 consecutive months.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction was reported for Envoy Medical (COCH)?

Envoy Medical reported a stock option grant to Interim CFO Robert Potashnick. He received options to purchase 15,000 shares of Class A common stock at an exercise price of $0.53 per share, aligning his compensation with the company’s future performance.

Who received stock options in this Envoy Medical (COCH) Form 4 filing?

Interim CFO Robert Potashnick received the stock options. As an officer of Envoy Medical, he was granted 15,000 stock options to buy Class A common shares, directly owned, with a long-term vesting schedule tied to continued service and performance.

What is the exercise price of the Envoy Medical (COCH) stock options granted?

The stock options granted to Interim CFO Robert Potashnick have an exercise price of $0.53 per share. This means he can buy Envoy Medical Class A common stock at $0.53 once the options vest and are exercisable under the award terms.

How many Envoy Medical (COCH) options does the insider own after this transaction?

After this transaction, Interim CFO Robert Potashnick beneficially owns 15,000 stock options. These options give him the right to purchase 15,000 shares of Envoy Medical Class A common stock at the specified exercise price, subject to the vesting schedule.

What is the vesting schedule for the Envoy Medical (COCH) options granted to the Interim CFO?

The options vest over several years. 3,750 options vest on February 5, 2027, while the remaining 11,250 options vest pro rata on the 5th of each month for 36 consecutive months, promoting long-term alignment with Envoy Medical’s performance.

Is the Envoy Medical (COCH) option grant to the Interim CFO a purchase or an award?

The transaction reflects an award of options, not an open-market purchase. The Form 4 shows transaction code “A” for an acquisition, indicating a stock option grant to Interim CFO Robert Potashnick as part of his compensation package.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/09/2026 - 05:45 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Potashnick Robert

(Last) (First) (Middle)

C/O 4875 WHITE BEAR PARKWAY

(Street)

WHITE BEAR LAKE MN 55110

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Envoy Medical, Inc. [ COCH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Interim CFO

3. Date of Earliest Transaction (Month/Day/Year)
02/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$0.53	02/05/2026		A		15,000		(1)	02/05/2036	Class A Common Stock	15,000	$0	15,000	D

Explanation of Responses:

1. Options to purchase 3,750 shares vest on 2/5/2027, and 11,250 shares vest pro rata on the 5th of each month thereafter for 36 consecutive months.

	/s/ Robert Potashnick	02/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.